Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pfizer Inc Announces FDA Approved Lyrica


Thursday, 21 Jun 2012 07:00am EDT 

Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury. Lyrica received a priority review designation for this new indication from the FDA. 

Company Quote

30.25
0.16 +0.53%
17 Apr 2014